Leukocytosis and ischemic vascular disease morbidity and mortality: Is it time to intervene?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 4, 2005, Pages 658-670

  Coller, Barry S ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Leukocytes; Myocardial infarction; Neutrophils; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOLYTIC AGENT; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; PADGEM PROTEIN;

ACUTE CHEST SYNDROME; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; CELL FUNCTION; CEREBROVASCULAR DISEASE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LEUKEMIA; LEUKOCYTE COUNT; LEUKOCYTE FUNCTION; LEUKOCYTOSIS; MICROANGIOPATHY; MORBIDITY; MORTALITY; NEUTROPHIL; NONHUMAN; PAIN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; SICKLE CELL ANEMIA; SIDE EFFECT; SMOKING; THROMBOSIS; VASCULAR DISEASE;

HUMANS; ISCHEMIA; LEUKOCYTOSIS; MORBIDITY; PROGNOSIS; VASCULAR DISEASES;

EID: 16244419437     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000156877.94472.a5     Document Type: Review

References (137)

1. White PD. Heart Disease. New York, NY: The MacMillan Company; 1949.
2. Cole D, Singian E, Katz L. The long-term prognosis following myocardial infarction, and some factors which affect it. Circulation. 1954;9:321-334.
3. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc. 1998;279:1477-1482.
4. Cooper HA, Exner DV, Waclawiw MA, Domanski MJ. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol. 1999;84:252-257.
5. Kammersgaard LP, Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Leukocytosis in acute stroke: relation to initial stroke severity, infarct size, and outcome: the Copenhagen Stroke Study. Journal of Stroke and Cerebrovascular Diseases. 1999;8:259-263.
6. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10 substudy. Circulation. 2000;102:2329-2334.
7. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary artery disease: prospective study and updated meta-analyses. BMJ. 2004;321:199-204.
8. Kyne L, Hausdorff JM, Knight E, Dukas L, Azhar G, Wei JY. Neutrophilia and congestive heart failure after acute myocardial infarction. Am Heart J. 2000;139:94-100.
9. Barron HV, Harr SD, Radford MJ, Wang Y, Krumholz HM. The association between white blood cell count and acute myocardial infarction mortality in patients > or =65 years of age: findings from the cooperative cardiovascular project. J Am Coll Cardiol. 2001;38:1654-1661.
10. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001;87:636-639,A10.
11. Hajj-Ali R, Zareba W, Ezzeddine R, Moss AJ. Relation of the leukocyte count to recurrent cardiac events in stable patients after acute myocardial infarction. Am J Cardiol. 2001;88:1221-1224.
12. Marchioli R, Avanzini F, Barzi F, Chieffo C, Di Castelnuovo A, Franzosi MG, Geraci E, Maggioni AP, Marfisi RM, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Valagussa F. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J. 2001;22:2085-2103.
13. Noto D, Barbagallo CM, Cavera G, Cefalu' AB, Caimi G, Marino G, Lo CL. Caldarella R, Notarbartolo A, Averna MR. Leukocyte count, diabetes mellitus and age are strong predictors of stroke in a rural population in southern Italy: an 8-year follow-up. Atherosclerosis. 2001;157:225-231.
14. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schutt A, Rippin G, Hafner G, Treude R, Othman H, Hofmann KP, Meyer J. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:901-908.
15. Maekawa Y, Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S, Mitamura H, Ogawa S. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol. 2002;39:241-246.
16. Albert AA, Beller CJ, Walter JA, Arnrich B, Rosendahl UP, Priss H, Ennker J. Preoperative high leukocyte count: a novel risk factor for stroke after cardiac surgery. Ann Thorac Surg. 2003;75:1550-1557.
17. Bagger JP, Zindrou D, Taylor KM. Leukocyte count: a risk factor for coronary artery bypass graft mortality. Am J Med. 2003;115:660-663.
18. Bhatt DL, Chew DP, Lincoff AM, Simoons ML, Harrington RA, Ommen SR, Jia G, Topol EJ. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol. 2003;92:136-140.
19. Dacey LJ, DeSimone J, Braxton JH, Leavitt BJ, Lahey SJ, Klemperer JD, Westbrook BM, Olmstead EM, O'Connor GT. Preoperative white blood cell count and mortality and morbidity after coronary artery bypass grafting. Ann Thorac Surg. 2003;76:760-764.
20. Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart. 2003;89:1200-1204.
21. Menon V, Lessard D, Yarzebski J, Furman MI, Gore JM, Goldberg RJ. Leukocytosis and adverse hospital outcomes after acute myocardial infarction. Am J Cardiol. 2003;92:368-372.
22. Yen MH, Bhatt DL, Chew DP, Harrington RA, Newby LK, Ardissino D, Van de WF, White JA, Moliterno DJ, Topol EJ. Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. Am J Med. 2003;115:318-321.
23. Byrne CE, FitzGerald A, Cannon CP, Fitzgerald DJ, Shields DC. Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes. BMC Med Genet. 2004;5:13.
24. Grau AJ, Boddy AW, Dukovic DA, Buggle F, Lichy C, Brandt T, Hacke W. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke. 2004;35:1147-1152.
25. Grzybowski M, Welch RD, Parsons L, Ndumele CE, Chen E, Zalenski R, Barron HV. The association between white blood cell count and acute myocardial infarction in-hospital mortality: findings from the National Registry of Myocardial Infarction. Acad Emerg Med. 2004;11:1049-1060.
26. Tong PC, Lee KF, So WY, Ng MH, Chan WB, Lo MK, Chan NN, Chan JC. White blood cell count is associated with macro- and microvascular complications in chinese patients with type 2 diabetes. Diabetes Care. 2004;27:216-222.
27. Yarnell JW, Patterson CC, Sweetnam PM, Lowe GD. Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart J. 2004;25:1049-1056.
28. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
29. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
30. Engstrom G, Hedblad B, Stavenow L, Jonsson S, Lind P, Janzon L, Lindgarde F. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler Thromb Vasc Biol. 2004;24:1498-1502.
31. Gurm H, Gupta R. The baseline leucocyte count is a strong and independent predictor of mortality in patients undergoing percutaneous coronary artery interventions: implications of arterial inflammation. Circulation. 2001;104:II775. Abstract.
32. Grau AJ, Buggle F, Becher H, Zimmermann E, Spiel M, Fent T, Maiwald M, Werle E, Zorn M, Hengel H, Hacke W. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. Neurology. 1998;50:196-203.
33. Ameriso SF, Wong VL, Quismorio FP Jr, Fisher M. Immunohematologic characteristics of infection-associated cerebral infarction. Stroke. 1991;22:1004-1009.
34. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618.
35. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, Bensinger WI. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 2000;25:85-89.
36. Matsubara H. Risk to the coronary arteries of intracoronary stem cell infusion and G-CSF cytokine therapy. Lancet. 2004;363:746-747.
37. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo LD, Sohn DW, Han KS, Oh BH, Lee MM, Park YB. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 2004;363:751-756.
38. Galimberti R, Pietropaolo N, Galimberti G, Kowalczuk A. Adult purpura fulminans associated with staphylococcal infection and administration of colony-stimulating factors. Eur J Dermatol. 2003;13:95-97.
39. Dereure O, Bessis D, Lavabre-Bertrand T, Exbrayat C, Fegueux N, Biron C, Guilhou JJ. Thrombotic and necrotizing panniculitis associated with recombinant human granulocyte colony-stimulating factor treatment. Br J Dermatol. 2000;142:834-836.
40. Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO III. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol. In press.
41. Barbui T, Finazzi G, Grassi A, Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factors - a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1996;75:368-371.
42. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004;10:171-178.
43. Nakamura S, Imamura T, Okamoto K. Tissue factor in neutrophils: yes. J Thromb Haemost. 2004;2:214-217.
44. Palmerini T, Coller BS, Cervi V, Tomasi L, Marzocchi A, Marrozzini C, Leone O, Piccioli M, Branzi A. Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system. J Am Coll Cardiol. 2004;44:1570-1577.
45. Winkel P, Statland BE, Saunders AM, Osborn H, Kupperman H. Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am J Clin Pathol. 1981;75:693-700.
46. Thomson SP, Gibbons RJ, Smars PA, Suman VJ, Pierre RV, Santrach PJ, Jiang NS. Incremental value of the leukocyte differential and the rapid creatine kinase-MB isoenzyme for the early diagnosis of myocardial infarction. Ann Intern Med. 1995;122:335-341.
47. Dale DC, Fauci AS, Guerry D, IV, Wolff SM. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest. 1975;56:808-813.
48. Fauci AS, Dale DC. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest. 1974;53:240-246.
49. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.
50. Nieto FJ, Szklo M, Folsom AR, Rock R, Mercuri M. Leukocyte count correlates in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1992;136:525-537.
51. Cavalot F, Massucco P, Perna P, Traversa M, Anfossi G, Trovati M. White blood cell count is positively correlated with albumin excretion rate in subjects with type 2 diabetes. Diabetes Care. 2002;25:2354-2355.
52. Woodman RJ, Watts GF, Puddey TB, Burke V, Mori TA, Hodgson JM. Beilin LJ. Leukocyte count and vascular function in type 2 diabetic subjects with treated hypertension. Atherosclerosis. 2002;163:175-181.
53. Blair SN, Kohl HW, III, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. J Am Med Assoc. 1989;262:2395-2401.
54. Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North Am men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med. 1988;319:1379-1384.
55. Blair SN, Kampert JB, Kohl HW III, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. J Am Med Assoc. 1996;276:205-210.
56. Church TS, Finley CE, Earnest CP, Kampert JB, Gibbons LW, Blair SN. Relative associations of fitness and fatness to fibrinogen, white blood cell count, uric acid and metabolic syndrome. Int J Obes Relat Metab Disord. 2002;26:805-813.
57. Fisch IR, Freedman SH. Smoking, oral contraceptives, and obesity. Effects on white blood cell count. J Am Med Assoc. 1975;234:500-506.
58. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol. 2001;153:242-250.
59. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150:341-353.
60. Zhang Z, Chopp M, Zhang RL, Goussev A. A mouse model of embolic focal cerebral ischemia. J Cereb Blood Flow Metab. 1997;17:1081-1088.
61. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights from the Framingham Study. J Am Med Assoc. 1992;267:1253-1256.
62. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Masoura C, Toutouzas P, Stefanadis C. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. Am J Med. 2004;116:145-150.
63. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 1997;96:1089-1096.
64. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med. 2002;30:S214-S219.
65. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation. 1989;80:1816-1827.
66. Thiagarajan RR, Winn RK, Harlan JM. The role of leukocyte and endothelial adhesion molecules in ischemia-reperfusion injury. Thromb Haemost. 1997;78:310-314.
67. Martinez-Mier G, Toledo-Pereyra LH, Ward PA. Adhesion molecules and hemorrhagic shock. J Trauma. 2001;51:408-415.
68. Hartl R, Schurer L, Schmid-Schonbein GW, del Zoppo GJ. Experimental antileukocyte interventions in cerebral ischemia. J Cereb Blood Flow Metab. 1996;16:1108-1119.
69. Heinel LA, Rubin S, Rosenwasser RH, Vasthare US, Tuma RF. Leukocyte involvement in cerebral infarct generation after ischemia and reperfusion. Brain Res Bull. 1994;34:137-141.
70. Yonekawa K, Harlan JM. Targeting leukocyte integrins in human diseases. J Leukoc Biol. 2004.
71. Palatianos GM, Balentine G, Papadakis EG, Triantafillou CD, Vassili MI, Lidoriki A, Dinopoulos A, Astras GM. Neutrophil depletion reduces myocardial reperfusion morbidity. Ann Thorac Surg. 2004;77:956-961.
72. Vamvakas EC. Platelet transfusion and adverse outcomes. Lancet. 2004; 364:1736-1738.
73. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343-1360.
74. Francis RB. Large-vessel occlusion in sickje cell disease: pathogenesis, clinical consequences, and therapeutic implications. Med Hypotheses. 1991;35;88-95.
75. Merkel KH, Ginsberg PL, Parker JC Jr, Post MJ. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke. 1978;9:45-52.
76. Steen RG, Xiong X, Langston JW, Helton KJ. Brain injury in children with sickle cell disease: prevalence and etiology. Ann Neurol. 2003;54:564-572.
77. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
78. Olatunji PO, Davies SC. The predictive value of white cell count in assessing clinical severity of sickle cell anaemia in Afro-Caribbeans patients. Afr J Med Med Sci. 2000;29:27-30.
79. Anyaegbu CC, Okpala IE, Akren'Ova YA, Salimonu LS. Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia (SCA). Eur J Haematol. 1998;60:267-268.
80. Okpala I. The intriguing contribution of white blood cells to sickle cell disease - a red cell disorder. Blood Rev. 2004;18:65-73.
81. Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K, Wethers DL, Bello JA, Vichinsky EP, Moser FG, Gallagher DM, DeBaun MR, Platt OS, Miller ST. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics. 1999;103:640-645.
82. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 1992;120:360-366.
83. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, Daeschner C, Manci EA. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855-1865.
84. Pieters RC, Rojer RA, Saleh AW, Saleh AE, Duits AJ. Molgramostim to treat SS-sickle cell leg ulcers. Lancet. 1995;345:528.
85. Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet. 1998;351:959.
86. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood. 2001;97:3313-3314.
87. Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood. 2001;97:3998-3999.
88. Okpala I, Daniel Y, Haynes R, Odoemene D, Goldman J. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur J Haematol. 2002;69:135-144.
89. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002;99:3047-3051.
90. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. J Am Med Assoc. 2003;289:1645-1651.
91. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322.
92. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039-2045.
93. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89:2319-2327.
94. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol. 2004;41:15-17.
95. Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol. 2004;41:18-22.
96. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95:3589-3593.
97. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol. 2003;74:26-31.
98. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med. 2000;133:925-926.
99. Rauch A, Borromeo M, Ghafoor A, Khoyratty B, Maheshwari J. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia. Blood 1999;94(suppl 1):415a. Abstract.
100. Al Jam'a AH, Al Dabbous IA, Al Khatti AA, Esan FG. Are we underestimating the leukemogenic risk of hydroxyurea. Saudi Med J. 2002;23:1411-1413.
101. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol. 2001;54:316-322.
102. Brown DW, Ford ES, Giles WH, Croft JB, Balluz LS, Mokdad AH. Associations between white blood cell count and risk for cerebrovascular disease mortality: NHANES II Mortality Study, 1976-1992. Ann Epidemiol. 2004;14:425-430.
103. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96:170-175.
104. Balasubramanian V, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood. 2002;100:2787-2792.
105. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004;95:858-866.
106. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 2004;104:3190-3197.
107. Goel MS, Diamond SL. Neutrophil cathepsin G promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets. J Biol Chem. 2003;278:9458-9463.
108. Goel MS, Diamond SL. Neutrophil enhancement of fibrin deposition under flow through platelet-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol. 2001;21:2093-2098.
109. Niemetz J, Marcus AJ. The stimulatory effect of platelets and platelet membranes on the procoagulant activity of leukocytes. J Clin Invest. 1974;54:1437-1443.
110. Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem. 1985;260:2119-2124.
111. McGee MP, Li LC. Functional difference between intrinsic and extrinsic coagulation pathways. Kinetics of factor X activation on human monocytes and alveolar macrophages. J Biol Chem. 1991;266:8079-8085.
112. Altieri DC, Morrissey JH, Edgington TS. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci U S A. 1988;85:7462-7466.
113. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol. 1996;28:345-353.
114. de Gaetano G, Evangelista V, Cerletti C. Should cardiologists forget about platelets and take an interest in blood leukocytes? Ital Heart J. 2000;1:453-456.
115. de Gaetano G, Cerletti C, Evangelista V. Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis. 1999;29:41-49.
116. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood. 1996;88:146-157.
117. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Hechtman HB, Michelson AD. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998;31:352-358.
118. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL III, Goldberg RJ, Michelson AD. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001;38:1002-1006.
119. Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, Scheiner T, Torbet J, Vilaire G, Bennett JS, Murciano JC, Muzykantov V, Penn MS, Hazen SL, Weisel JW, Ischiropoulos H. Pro-thrombotic state induced by post-transtational modification of fibrinogen by reactive nitrogen species. J Biol Chem. 2004;279:8820-8826.
120. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol. 1983;111:98-111.
121. Meisel SR, Shapiro H, Radnay J, Neuman Y, Khaskia AR, Gruener N. Pauzner H, David D. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: possible implications for leukocyte aggregation and microvascular plugging. J Am Coll Cardiol. 1998;31:120-125.
122. Bednar M, Smith B, Pinto A, Mullane KM. Neutrophil depletion suppresses 111In-labeled platelet accumulation in infarcted myocardium. J Cardiovasc Pharmacol. 1985;7:906-912.
123. Ishikawa M, Zhang JH, Nanda A, Granger DN. Inflammatory responses to ischemia and reperfusion in the cerebral microcirculation. Front Biosci. 2004;9:1339-1347.
124. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr, Hazen SL. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134-1139.
125. Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol. 2003;14:353-359.
126. Zhang R, Brennan ML, Fu X, A viles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. J Am Med Assoc. 2001;286:2136-2142.
127. Naskalski JW, Marcinkiewicz J, Drozdz R. Myeloperoxidase-mediated protein oxidation: its possible biological functions. Clin Chem Lab Med. 2002;40:463-468.
128. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res. 2004;61:461-470.
129. Coleman LG Jr, Polanowska-Grabowska RK, Marcinkiewicz M, Gear AR. LDL oxidized by hypochlorous acid causes irreversible platelet aggregation when combined with low levels of ADP, thrombin, epinephrine, or macrophage-derived chemokine (CCL22). Blood. 2004;104:380-389.
130. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, Heinecke JW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A. 2004;101:13032-13037.
131. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61-67.
132. Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Coller BS. β3-integrin-deficient mice, but not P-selectin-deficient mice, develop intimai hyperplasia after vascular injury. Circulation. 2001;103:2501-2507.
133. Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation. 1997;96:4333-4342.
134. Akers DL, Lefer DJ, Chen IL, Wilkens RG, Rice J, Aurora H, Osgood TA, Bedi B, Tenaglia AN, Buda AJ, Kadowitz PJ, McNamara DB. Effect of short-term treatment with a monoclonal antibody to P-selectin on balloon catheter-induced: intimal hyperplasia, re-endothelialization, and attenuation of endothelial-dependent relaxation. Mol Cell Biochem. 1997;176:13-20.
135. Wang K, Zhou Z, Zhou X, Tarakji K, Topol EJ, Lincoff AM. Prevention of intimai hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J Am Coll Cardiol. 2001;38:577-582.
136. Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Topol EJ, Lincoff AM, Wang K. Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. Arterioscler Thromb Vasc Biol. 2002;22:1598-1603.
137. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 2002;106:1523-1529.